{
    "2018-04-18": [
        [
            {
                "time": "2018-04-18",
                "original_text": "明日最具投资机会六大牛股一览（2018年4月18日）",
                "features": {
                    "keywords": [
                        "投资机会",
                        "牛股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "[买入-A评级]恒瑞医药(600276)动态分析：业绩符合预期 国内外双线布局将助力公司进一步成长",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩",
                        "国内外双线布局"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "33亿外资抄底！深股通资金流入创开通以来单日新高",
                "features": {
                    "keywords": [
                        "外资抄底",
                        "深股通",
                        "资金流入"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "817家公司现国家队身影，白马股分歧，创蓝筹受青睐",
                "features": {
                    "keywords": [
                        "国家队",
                        "白马股",
                        "创蓝筹"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "抗癌药零关税 急需药加快进医保 四股可以持续关注",
                "features": {
                    "keywords": [
                        "抗癌药",
                        "零关税",
                        "急需药",
                        "医保"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "[买入评级]恒瑞医药(600276)年报点评：业绩分析业绩高于预期;18年关注新上市产品",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "年报",
                        "业绩高于预期",
                        "新上市产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "【陆股通交易追踪】陆股通逆势净流入6.88亿元 海康威视等电子股遭抛售",
                "features": {
                    "keywords": [
                        "陆股通",
                        "净流入",
                        "海康威视",
                        "电子股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "电子"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "创新药步入收获期 国际化战略稳步推进",
                "features": {
                    "keywords": [
                        "创新药",
                        "国际化战略"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "医药板块大幅回调 风险还是机会",
                "features": {
                    "keywords": [
                        "医药板块",
                        "回调",
                        "风险",
                        "机会"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-18",
                "original_text": "恒瑞医药2017年年报点评:收入增速超预期,重磅新药将陆续上市",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "年报",
                        "收入增速超预期",
                        "重磅新药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}